FDA Fast-Tracks Talactoferrin/Sunitinib for Renal Cell Carcinoma

Publication
Article
OncologyONCOLOGY Vol 23 No 7
Volume 23
Issue 7

Agennix announced that talactoferrin alfa has been granted Fast Track designation by the FDA for the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent).

Agennix announced that talactoferrin alfa has been granted Fast Track designation by the FDA for the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent). The Fast Track program is designed to expedite the review of investigational drugs for the treatment of patients with serious or life-threatening diseases where there is an unmet medical need.

Articles in this issue
What Is the Optimal Initial Treatment of Low-Risk Papillary Thyroid Cancer (and Why Is It Controversial)?
What Is the Optimal Initial Treatment of Low-Risk Papillary Thyroid Cancer (and Why Is It Controversial)?
Low-Risk Papillary Thyroid Cancer: Treatment Options and Patient Perceptions
Can Risk-Adapted Treatment Recommendations Replace the ‘One Size Fits All’ Approach for Early-Stage Thyroid Cancer Patients?
Prophylactic Central Lymph Node Dissection: Continued Controversy
Music Therapy
Music Therapy
LHRH Antagonists vs LHRH Agonists: Which Is More Beneficial in Prostate Cancer Therapy?
Is There a Role for LHRH Antagonists in Prostate Cancer?
Important Considerations in LHRH Antagonist Therapy for Prostate Cancer
The Role of LHRH Antagonists in the Treatment of Prostate Cancer
Maintenance Therapy With Pemetrexed Improves Overall Survival in Advanced NSCLC
PARP Inhibitors Show Promise for Hard-to-Treat Breast Cancers
Therapeutic Cancer Vaccine Significantly Prolongs Disease-Free Survival for Follicular Lymphoma
Vaccine Improves Response Rate and Extends Progression-Free Survival in Metastatic Melanoma
‘Natural’ Hormone Replacement and Breast Cancer Risk: Evidence for Safety and Efficacy
Phase IIIB Trial of Intermittent Degarelix Therapy Launched
Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Related Content
This trial combines pembrolizumab and trabedersen to enhance treatment for advanced NSCLC, targeting TGF-β2 for improved patient outcomes.

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

Omar K. Abughanimeh, MBBS;Anthony E. Maida III, PhD, MA, MBA;Sanjive Qazi, PhD;Kate-Lynn Muir, DO;Bhavina Sharma MD;Lynette Smith, PhD;Apar Kishor Ganti, MD
October 30th 2025
Article

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.

3 Things You Should Know About Single-Agent ADCs in TNBC Treatment

ONCOLOGY Staff
October 29th 2025
Article

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.

Late Hepatic Recurrence From Granulosa Cell Tumor: A Case Report

Prosper Akankwasa, MBBS;Jackson Kakooza, MBBS;Aisha Abdullahi Ahmed, MBBS;Catherine R. Lewis, MD, PhD
October 28th 2025
Article

Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.

Explore a rare case of vulvar epithelioid sarcoma, highlighting the role of SMARCB1 loss and the challenges of radiotherapy in treatment.

Unraveling the Complexities of Proximal-Type Epithelioid Sarcoma of the Vulva

Fatimah M. Kaabi, MBBS;Chaker Zaidi, MD, PhD;Fatimah Abdullah Alessa, MBBS;Yasser Sorour, MD, PhD
October 27th 2025
Article